Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02485652 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Phase 2 study, sponsored by Hanmi Pharmaceutical Company Limited.
- Terminated
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT02485652: Clinical Trial Phase 2 study, sponsored by Hanmi Pharmaceutical Company Limited.
NCT02485652 is a Phase 2 study that was terminated before completion, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 162 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02485652, a Phase 2 study, was terminated before completion, sponsored by Hanmi Pharmaceutical Company Limited.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
Primary Outcome
To assess the anti-tumor efficacy of HM61713 as measured by objective response rate (ORR).
Interventions
- DRUG HM61713
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2015-08-31 |
| Est. Completion | 2020-12-08 |
| Phase | Phase 2 |
Why NCT02485652 stopped before completion
NCT02485652 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% higher).
The record links to 0 conditions, and to 1 intervention - of which HM61713 is the first listed.
NCT02485652 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02485652 about?
NCT02485652 is a clinical study titled "Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung". The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
What is the current status of trial NCT02485652?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2015-08-31. Estimated completion is 2020-12-08.
What interventions are being tested in trial NCT02485652?
The interventions under investigation include: HM61713 (DRUG).
Who is sponsoring clinical trial NCT02485652?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02485652's enrollment target sits among peer trials
162 418th of 2000 higher than 1,579 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI